EGFR and cancer: The researchers report that the overexpression of YAP/TAZ in cancer is an important type of resistance in this therapy, mainly in the context of the epidermal growth factor receptor (EGFR) and mitogen-activated protein kinase (MAPK) inhibitors [132,133].